Press release content from KISSPR. The AP news staff was not involved in its creation.
Can HIV Patients get Hair Transplant in Turkey?
April 3, 2021 GMT
Can HIV Patients get Hair Transplant in Turkey?
04/03/2021, Istanbul, Turkey // KISSPR //
Hair loss makes everyone unhappy in the same way, and HIV-positive individuals should have the opportunity to benefit from hair transplantation and improve their appearance. Other patients and provided that the safety of the teams who get the hair make possible hygienic clinical environment creating an extremely successful hair transplantation surgery in Turkey to HIV-positive individuals.
Ixora Life Clinic provides a new page to open their lives with the implantation to support the HIV-positive patient’s towards a positive life with the highest hygiene standards in Turkey and an experienced team of Hiv positive hair transplant doctors.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AHF Backs WTO Chief’s Appeal for Vaccine Equity
April 1, 2021 GMT
LOS ANGELES (BUSINESS WIRE) Apr 1, 2021
In response to abhorrent inequality in the global distribution of COVID-19 vaccines among wealthy and developing countries, World Trade Organization (WTO) Director-General Dr. Ngozi Okonjo-Iweala has called on government leaders and vaccine manufacturers to negotiate fairer terms for economically challenged nations. AIDS Healthcare Foundation ( AHF ), the largest provider of HIV/AIDS care and treatment globally, which operates in 45 countries, fully supports WTO’s appeal for vaccine equity.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 .
CytoDyn Inc.April 1, 2021 GMT
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend tre
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent
GeoVax, Inc.April 1, 2021 GMT
Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide
Atlanta, GA - ( NewMediaWire ) - April 01, 2021 - GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 16/305,305 entitled “Composition and Methods of Generating an Immune Response to Hepatitis B Virus.”